Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine.

Bruce GreenHerta CrauwelsThomas N KakudaSimon VanveggelAnne Brochot

Published in: Clinical pharmacokinetics (2017)

In this analysis, body weight, CLCR, and CYP2C9/CYP2C19 phenotype were found to describe some of the variability in CL/F. It was not possible to show an impact of concomitant antiretrovirals on the pharmacokinetics of etravirine for adults predominantly taking coadministered boosted protease inhibitors as a background antiretroviral regimen.

Keyphrases

body weight
hiv infected
human immunodeficiency virus
hiv positive
hiv infected patients
antiretroviral therapy
african american